U.S. IMPORTERS' QUESTIONNAIRE

METHIONINE FROM FRANCE, JAPAN, AND SPAIN

This questionnaire must be received by the Commission by March 26, 2021

See last page for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping investigations concerning methionine from France, Japan, and Spain (Inv. Nos. 731-TA-1534-1536 (Final)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm _____

| City | | | Sta | ate | Zi | ip Cod | e | | | _ | |
|--|---|---|--|---|---|--|--|--|---|----------|---|
| Website _ | | | | | | | | | | _ | |
| Has your fir 2018? | m imported m | ethionine (as de | fined on next | page) fro | m any (| country | at any tim | e since Ja | inuary 1, | | |
| ☐ NO | (Sign the ce | rtification below a | and promptly re | eturn only t | this pag | ge of the | questionna | re to the C | Commission | 1) | |
| YES | (Complete a | II parts of the que | estionnaire, and | d return the | e entire | e questio | nnaire to th | e Commiss | ion) | | |
| • | | ia the U.S. Inte | | | | | , | | | | |
| | | | | | | | | | | | |
| e and belief | and understa | in supplied in nd that the info trant consent f | response to rmation subr | mitted is s | ubject | t to aud | it and ver | fication l | y the Co | nmission | Ву |
| e and belief this certific on provided dission on the dersigned, ac g or other p (a) for deve and evaluat 3; or (ii) by | and understar ation I also g in this question same or simil knowledge the roceedings mail loping or mail ons relating i J.S. governme | • • | response to rmation subroughout this poughout this poughout this poughout this poughous of this poughous of this poughous of this poughout pure to and contract poughous pough | this ques mitted is s nission, an proceedin n responso : (i) by the or a relate l, and opports | subject nd its g in ar e to the e Comi ed pro- | t to aud emplo ny othe his requ emission oceeding | lit and ver yees and r import-in uest for in , its emplo g, or (b) in he Commi | fication la contract njury prod formation nyees and internal ssion inc | by the Col personned ceedings of a and thr I Offices, investiga luding un | mmission | By the by this act lits, |
| e and belief this certific on provided dission on the dersigned, ac g or other p (a) for deve and evaluat 3; or (ii) by | and understar ation I also g in this question same or similal knowledge the roceedings mail loping or mail ons relating in J.S. governme I sign appropri | nd that the info grant consent f nnaire and thro ar merchandise at information by be disclosed ntaining the re- to the progran nt employees a | response to rmation subroughout this pubmitted in to and used: cords of this ins, personnel and contract pure agreemen | this ques mitted is s nission, an proceeding n response : (i) by the or a relate l, and ope personnel, ts. | subject nd its g in ar e to the e Comi ed pro- | t to aud emplo ny othe his requ emission oceeding | lit and ver yees and r import-in uest for in , its emplo g, or (b) in he Commi | fication la contract njury prod formation nyees and internal ssion inc | by the Col personned ceedings of a and thr I Offices, investiga luding un | mmission | By the by this act lits, |

PART I.—GENERAL INFORMATION

Background.--This proceeding was instituted in response to petitions filed on July 29, 2020, by Novus International, Inc., St. Charles, Missouri. Antidumping duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of dumping. Questionnaires and other information pertinent to this proceeding are available at

https://www.usitc.gov/investigations/701731/2020/methionine france japan and spain/final.htm.

<u>Methionine</u> covered by these investigations is methionine and dl-Hydroxy analogue of dlmethionine, also known as 2-Hydroxy 4-(Methylthio) Butanoic acid (HMTBa), regardless of purity, particle size, grade, or physical form. Methionine has the chemical formula $C_5H_{11}NO_2S$, liquid HMTBa has the chemical formula $C_5H_{10}O_3S$, and dry HMTBa has the chemical formula $(C_5H_9O_3S)_2Ca$.

Subject merchandise also includes methionine processed in a third country including, but not limited to, refining, converting from liquid to dry or dry to liquid form, or any other processing that would not otherwise remove the merchandise from the scope of these investigations if performed in the country of manufacture of the in-scope methionine or dl-Hydroxy analogue of dl-methionine.

The scope also includes methionine that is commingled (i.e., mixed or combined) with methionine from sources not subject to these investigations. Only the subject component of such commingled products is covered by the scope of these investigations.

Excluded from this investigation is United States Pharmacopoeia (USP) grade methionine. In order to qualify for this exclusion, USP grade methionine must meet or exceed all of the chemical, purity, performance, and labeling requirements of the United States Pharmacopeia and the National Formulary for USP grade methionine.

Methionine is currently classified under subheadings 2930.40.0000 and 2930.90.4600 of the Harmonized Tariff Schedule of the United States (HTSUS). Methionine has the Chemical Abstracts Service (CAS) registry numbers 583-91-5, 4857-44-7, 59-51-8 and 922-50-9. While the HTSUS subheadings and CAS registry numbers are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

<u>Importer</u>.--Any person or firm engaged, either directly or through a parent company or subsidiary, in importing methionine (as defined above) into the United States from a foreign manufacturer or through its selling agent.

<u>Reporting of information</u>.--If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

<u>Valid number error messages.</u>--If you are completing this form in a country that uses periods (".") to delineate multiples of 1000 (e.g., one million would appear as \$1.000.000 rather than \$1,000,000), you may be unable to enter in numbers greater than 999 in numeric form fields. The solution to this data entry issue is to temporarily change your operating system's number formatting to be consistent with the U.S. number formatting system while you complete this form. Detailed instructions on how to resolve this issue is provided at the end of this questionnaire and is available upon request from Calvin Chang (202-205-3062, <u>calvin.chang@usitc.gov</u>).

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is *optional*. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

| U.S. Importers' Questio | nnaire - Methionine (| (Final |
|-------------------------|------------------------------|--------|
|-------------------------|------------------------------|--------|

| I-1. | OMB statisticsPlease report below the actual number of hours required and the cost to your |
|------|--|
| | firm of completing this questionnaire. |

| Hours | Dollars |
|-------|---------|
| | |

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 40 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please attach such comments to your response or send to the Office of Investigations, USITC, 500 E St. SW, Washington, DC 20436.

| I-2a. | Establishments covered Provide the name and address of establishment(s) covered by this |
|-------|--|
| | questionnaire. |

| "Establishment"E | each facility of a firm involved in | the <u>importation</u> of methioning | e, including |
|------------------------|-------------------------------------|--------------------------------------|---------------|
| auxiliary facilities o | perated in conjunction with (wh | hether or not physically separa | te from) such |
| facilities. | | | |

- I-2b. <u>Stock symbol information.</u>— If your firm or parent firm is publicly traded, please specify the stock exchange and trading symbol: _____.
- I-2c. <u>External counsel.</u>— If your firm or parent firm is represented by external counsel in relation to this proceeding, please specify the name of the law firm and the lead attorney(s).

| Law firm: | |
|-------------------|--|
| Lead attorney(s): | |

| U.S. I | mporters' Quest | ionnaire - Methio r | nine (Final) | Page 5 | | |
|--------|-----------------|--|---|-------------------------------|--|--|
| I-3. | Ownership | Is your firm owned | l, in whole or in part, by any other firm? | | | |
| | ☐ No | ☐ No ☐ YesList the following information, relating to the ultimate parent/owner. | | | | |
| | Firm name | | Country | Extent of ownership (percent) | | |
| | | | | | | |
| I-4. | foreign, that a | are engaged in imp are engaged in ex | Does your firm have any related firms, either porting methionine from France, Japan, and Sporting methionine from France, Japan, and following information. | Spain into the United | | |
| | Firm name | | Country | Affiliation | | |
| | Timmanic | | Country | / made on | | |
| | | | | | | |
| | | | | | | |
| I-5. | | e production of m | firm have any related firms, either domestic ethionine? following information. | or foreign, that are | | |
| | Firm name | | Country | Affiliation | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| 115 | Importors' | Questionnaire | - Mothionina | /Einal |
|------|------------|---------------|--------------|---------|
| U.S. | importers | Questionnaire | - wetnionine | trinaii |

| Importer of record | Takes title to the imported product(s) | Consigne imported p | | Customs be freight for |
|--|--|--|--|---|
| | | |] | |
| | n is an importer of record ow (firm name, address, t | | | dividual to cor |
| Firm name | Address | | | Contact pand phor |
| | | | | |
| | | | | |
| _ | s a designated location in | | | - |
| procedures that allow ovell as other savings. A | s a designated location in delayed or reduced custo A foreign trade zone mus th in the Foreign-Trade Z | oms duty paym It be designate | ents on fore | eign merchan |
| procedures that allow overlass other savings. And procedures set for "Bonded warehouse" imports are stored penother charges. A bonded | delayed or reduced custon A foreign trade zone must the in the Foreign-Trade Zes a secured facility super ding their re-export, or red warehouse must be detailed. | oms duty paym ones designate ones Act. vised by U.S. c elease after pa | uents on fore d as such pu ustoms, whe ayment of im | eign merchand irsuant to the ere dutiable la inport duties, t |
| procedures that allow of well as other savings. A and procedures set for "Bonded warehouse" is imports are stored penother charges. A bonded procedures set forth in "Temporary Importation merchandise may be enfree of duty. Under the etc. that would otherw merchandise within a secretain categories of merchandise of merchandise within a secretain categories within a secretain categories within a secretain categories within a secretain categories within a secretain cate | delayed or reduced custon A foreign trade zone must the in the Foreign-Trade Zes a secured facility super ding their re-export, or red warehouse must be detailed. | oms duty payment be designated ones Act. vised by U.S. of elease after presented as such as s | ustoms, when a year to cedure when the comment of impursuant to the comment of th | eign merchandersuant to the ere dutiable land port duties, for the rules and ereby imported the United mount of dutions or destroygram is restricted. |
| well as other savings. A and procedures set for "Bonded warehouse" i mports are stored pen other charges. A bonded procedures set forth in "Temporary Importation merchandise may be entered of duty. Under the etc. that would otherw merchandise within a secretain categories of merchandise of merchandise within a secretain categories within a secretain | delayed or reduced custors foreign trade zone must the in the Foreign-Trade Z is a secured facility super ding their re-export, or red warehouse must be decay 19 U.S.C. § 1555. In under Bond ("TIB") proportion to the important program, an importer program, an importer projectified time or pay liquer erchandise listed in subtedule of the United State | oms duty payment be designated ones Act. vised by U.S. of elease after presented as such as s | ustoms, when a year to cedure when the comment of impursuant to the comment of th | eign merchand irsuant to the ere dutiable la port duties, to the rules an ereby import nto the Unite mount of dut ort or destroy gram is restric |
| well as other savings. And procedures set for and procedures set for a mports are stored pendencedures set for a mports are stored pendencedures set forth in a free of duty. Under the etc. that would otherw merchandise within a startain categories of marmonized Tariff Scheller | delayed or reduced custors foreign trade zone must the in the Foreign-Trade Z is a secured facility super ding their re-export, or red warehouse must be decay 19 U.S.C. § 1555. In under Bond ("TIB") proportion to the important program, an importer program, an importer projectified time or pay liquer erchandise listed in subtedule of the United State | oms duty payment be designated ones Act. vised by U.S. of elease after presigned as such as such as such as a post of the program" is a post of the program | ustoms, when a year to be a such pure ustoms, when a year to be a year to be a year. This program to be a year to be a year. This program to be a year to be a year. This program to be a year to be a year. This program to be a year. This program to be a year. | eign merchan irsuant to the ere dutiable la port duties, to the rules an ereby import nto the Unite mount of dut ort or destroy gram is restric |
| brocedures that allow of well as other savings. A and procedures set for "Bonded warehouse" is mports are stored pendither charges. A bonded brocedures set forth in "Temporary Importation merchandise may be extracted to the world otherword was also be extracted to the world otherword merchandise within a secretain categories of metarmonized Tariff Scheller | delayed or reduced custors foreign trade zone must the in the Foreign-Trade Z is a secured facility super ding their re-export, or red warehouse must be decay 19 U.S.C. § 1555. In under Bond ("TIB") proportion to the important program, an importer program, an importer projectified time or pay liquer erchandise listed in subtedule of the United State | oms duty payment be designated ones Act. vised by U.S. of elease after presigned as such as such as such as a post of the program" is a post of the program | ustoms, when a year to be a such pure ustoms, when a year to be a year to be a year. This program to be a year to be a year. This program to be a year to be a year. This program to be a year to be a year. This program to be a year. This program to be a year. | eign merchar irsuant to the ere dutiable iport duties, to the rules a dereby impor into the Unite mount of du fort or destroy gram is restri |

| I-9. | Other trade actions To your knowledge, have the products subject to this proceeding been the |
|------|--|
| | subject of any other import relief proceedings in the United States or in any other countries? |

| No | Yes | If yes, Yes-Please specify. |
|----|-----|-----------------------------|
| | | |

PART II.--TRADE AND RELATED INFORMATION

Telephone

Further information on this part of the questionnaire can be obtained from Calvin Chang (202-205-3062, calvin.chang@usitc.gov). **Supply all data requested on a** calvin.chang@usitc.gov). **Supply all data requested on a** calvin.chang@usitc.gov).

| II-1. | <u>Contact information</u> Please identify the responsible individual and the manner by which | | | | |
|-------|---|--|--|--|--|
| | Commission staff may contact that individual regarding the confidential information submitted in part II. | | | | |
| | Name | | | | |
| | Title | | | | |
| | Fmail | | | | |

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the importation of methionine since January 1, 2018.

| (che | ck as many as appropriate) | (If checked, please describe the nature, date(s), and significance of any such reported changes as well as the business reasons for them; leave completely blank if not applicable) |
|------|---|---|
| | Office/warehouse openings | |
| | Office/warehouse closings | |
| | Relocations | |
| | Expansions | |
| | Acquisitions | |
| | Consolidations | |
| | Prolonged shutdowns or importation curtailments | |
| | Revised labor agreements | |
| | Other (e.g., technology) | |

| | | | _ | | |
|-----|------------|-----------|---------|------------|---------|
| 115 | Importers' | Ouestions | naire - | Methionine | (Final) |
| | | | | | |

II-2b. <u>COVID-19 pandemic.</u>-- Since January 1, 2020, has the COVID-19 pandemic or have any government actions taken to contain the spread of the COVID-19 virus resulted in changes in relation to your firm's supply arrangements, importation, employment, and shipments relating to methionine?

| No | Yes | If yes, describe these changes including a separate discussion of the (a) supply chain impact, (b) importation and shipments impact, and (c) employment impact of the COVID-19 pandemic. |
|----|-----|--|
| | | |

II-3a. <u>Arranged imports</u>.--Has your firm imported or arranged for the importation of methionine for delivery after **December 31, 2020**?

"Arranged imports" are imports for which your firm has placed an order with a foreign supplier for subject merchandise, but delivery of those imports is not scheduled to occur until after the date listed above.

| No | Yes | |
|----|-----|-----------------------------------|
| | | If yes, fill out the table below. |

| | Period | | | |
|-------------------|--------------|--------------|---------------|--------------|
| Source | Jan-Mar 2021 | Apr-Jun 2021 | Jul-Sept 2021 | Oct-Dec 2021 |
| | | Quantity (in | short tons) | |
| France | | | | |
| Japan | | | | |
| Spain | | | | |
| All other sources | | | | |

| II-3b. | Imports in the 12-month period preceding the petitionHas your firm imported methionine |
|--------|--|
| | from any source between July 1, 2019 and June 30, 2020? (i.e., the last six months in 2019 and |
| | first six months in 2020 combined) |

| No | Yes | |
|----|-----|---|
| | | If yes, report the quantity of such import below by source. |

| Quantity (in sho | ort tons) |
|-------------------|-----------------------------|
| Source | July 2019 through June 2020 |
| France | |
| Japan | |
| Spain | |
| All other sources | |

| II-4. | Reasons for importing if producerIf your firm also produces methionine in the United States, |
|-------|--|
| | please indicate the reasons for importing this product. If your firm's reasons differ by source, |
| | please elaborate. |
| | |
| | |

Definitions

"Imports" –Those products identified for Customs purposes as imports for consumption for which your firm was the importer of record (i.e., was responsible for paying any import duty).

"Import quantities" –Quantities reported should be net of returns.

"Import values"—Values reported should be landed, duty-paid values at the U.S. port of entry, including ocean freight and insurance costs, brokerage charges, and import duties (i.e., all charges except inland freight in the United States).

"Commercial U.S. shipments"— Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments"— Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" -- Finished goods inventory, not raw materials or work in progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-5a. <u>U.S. imports from France</u>.—Report your firm's imports and your firm's shipments and inventories of methionine imported from France by your firm during the specified period.

France

| , | uantity (in short tons), | Calendar year | |
|--|---|------------------------------------|------|
| ltem | 2018 | 2019 | 2020 |
| Beginning-of-period inventories (quantity) (A) | | | |
| Imports: ¹ Quantity (B) | | | |
| Value (C) | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | |
| Value (E) | | | |
| Internal consumption: ² Quantity (F) | | | |
| Value² (G) | | | |
| Transfers to related firms: ² Quantity (H) | | | |
| Value² (I) | | | |
| Export shipments: ³ Quantity (J) | | | |
| Value (K) | | | |
| End-of-period inventories (quantity) (L) | | | |
| ¹ Please identify the foreign producers, ² Internal consumption and transfers to basis for valuing these transactions in you the data provided above in this table shou | related firms must be var r records, please specify Ild be based on fair mark | that basis (e.g., cost, cost plus, | |

II-5a. **U.S. imports from France.**—Continued

<u>RECONCILIATION OF SHIPMENTS, IMPORTS, AND INVENTORIES.</u>—Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line A), plus imports (i.e., line B), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation | 2018 | 2019 | 2020 |
| A + B - D - F - H - J - L = should equal | | | |
| zero ("0") or provide an explanation.1 | 0 | 0 | 0 |
| ¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless | | | |

accurate: _____.

II-5b. Channels of distribution: France. -- Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of imports from France by channel of distribution during the specified periods.

France

| | Calendar year | | |
|---|---------------|--------------------------|------|
| Item | 2018 | 2019 | 2020 |
| | | Quantity (in short tons) | |
| Channels of distribution: U.S. shipments: To distributors (M) | | | |
| To end users (N) | | | |

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "O"), the data reported must be revised prior to submission to the Commission.

| | | Calendar year | |
|--|------|---------------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| M + N - D - F - H = zero ("0"), if not | | | |
| revise. | 0 | 0 | 0 |

II-5c. <u>U.S. shipments by type: France</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of methionine imported from France by product type during the specified period.

France

| Quantity (in short tons) and value (in \$1,000) | | | |
|---|------|---------------|------|
| ltem | | Calendar year | |
| | 2018 | 2019 | 2020 |
| U.S. shipments: DL-methionine, solid-form 99 | | | |
| activity level: Quantity (O) | | | |
| Value (P) | | | |
| DL-hydroxy analogues, solid-form 84 activity level: Quantity (Q) | | | |
| Value (R) | | | |
| DL-hydroxy analogues, liquid- form 88 activity level: <i>Quantity</i> (S) | | | |
| Value (T) | | | |
| All other products¹: Quantity (U) | | | |
| Value (V) | | | |
| ¹ Please specify these products: | | • | • |

<u>RECONCILIATION OF U.S. SHIPMENTS BY TYPE</u>.--Please ensure that the quantities and value reported for US shipments by type (i.e., lines O through V) summed across both columns equal the quantities and values reported for U.S. shipments (i.e., lines D through I) in part "a" of this question for each calendar year. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| Quantity: $O + Q + S + U - D - F - H =$ zero ("0"), if not revise. | 0 | 0 | 0 |
| Value: $P + R + T + V - E - G - I = zero$ ("0"), if not revise. | 0 | 0 | 0 |

- II-5d. Monthly U.S. imports: France.—Report your firm's monthly U.S. imports of methionine from France by supplier during the specified period.
 - Adisseo France
 - All other suppliers in France (Others)

| Quantity (in short tons) | | |
|--------------------------|--------------------|--------|
| | Supplier in France | |
| Month | Adisseo France | Others |
| 2020 | | |
| January | | |
| February | | |
| March | | |
| April | | |
| May | | |
| June | | |
| July | | |
| August | | |
| September | | |
| October | | |
| November | | |
| December | | |
| 2021 | | |
| January | | |
| February | | |

| <u>RECONCILIATION OF MONTHLY IMPORTS</u> Please ensure that the total imports reported for full year |
|--|
| 2020 reported in part "a" of this question matches the monthly data reported here. If the calculated |
| fields below return values other than zero (i.e., "0"), the data reported must be revised prior to |
| submission. |

| Interact with check box to update the calculations presented |
|--|
|--|

| Reconciliation for | Calendar year 2020 |
|--|--------------------|
| U.S. imports from France (line B), revise if not | |
| returning zero ("0") | 0 |

II-5e. <u>End-of-period inventories: France</u>.--Report your firm's end-of-period inventories of methionine in the United States of imports from France at the end of the specified month by supplier.

France

| q | uantity (in short tons) | |
|---|-------------------------|--------|
| | Supplier in France | |
| Date | Adisseo France | Others |
| Ending inventory balance on or around July 31, 2020 | | |
| August 31, 2020 | | |
| September 30, 2020 | | |
| October 31, 2020 | | |
| November 30. 2020 | | |
| December 31, 2020 | | |
| January 31, 2021 | | |
| February 28, 2021 | | |

| <u>RECONCILIATION OF END-OF-PERIOD INVENTORIES</u> Please ensure that the end-of-period inventories |
|--|
| reported for December 31, 2020 in this table across all suppliers match the aggregated data reported for |
| end-of-period inventories in part "a" of this question for calendar year 2020. If the calculated fields |
| below return values other than zero (i.e., "0"), the data reported must be revised prior to submission. |

| Reconciliation for | Calendar year 2020 |
|--|--------------------|
| End-of-period inventories from France (line L), revise | |
| if not returning zero ("0") | 0 |

II-6a. <u>U.S. imports from Japan</u>.—Report your firm's imports and your firm's shipments and inventories of methionine imported from Japan by your firm during the specified period.

Japan

| | Quantity (in short tons) | , value (<i>in \$1,000</i>) | |
|---|--|-----------------------------------|------|
| | Calendar year | | |
| Item | 2018 | 2019 | 2020 |
| Beginning-of-period inventories (quantity) (A) | | | |
| Imports: ¹ Quantity (B) | | | |
| Value (C) | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | |
| Value (E) | | | |
| Internal consumption: ² Quantity (F) | | | |
| Value² (G) | | | |
| Transfers to related firms: ² Quantity (H) | | | |
| Value² (I) | | | |
| Export shipments: ³ Quantity (J) | | | |
| Value (K) | | | |
| End-of-period inventories (quantity) (L) | | | |
| Please identify the foreign produce Internal consumption and transfers basis for valuing these transactions in y the data provided above in this table sh Identify your firm's principal export | to related firms must be vour records, please specify nould be based on fair mar | that basis (e.g., cost, cost plus | |

II-6a. **U.S. imports from Japan.**—Continued

<u>RECONCILIATION OF SHIPMENTS, IMPORTS, AND INVENTORIES.</u>—Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line A), plus imports (i.e., line B), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation | 2018 | 2019 | 2020 |
| A + B - D - F - H - J - L = should equal | | | |
| zero ("0") or provide an explanation.1 | 0 | 0 | 0 |
| ¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless | | | |

¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:

II-6b. <u>Channels of distribution: Japan</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of imports from Japan by channel of distribution during the specified period.

Japan

| | Calendar year | | |
|---|---------------|--------------------------|------|
| Item | 2018 | 2019 | 2020 |
| | | Quantity (in short tons) | |
| Channels of distribution: U.S. shipments: To distributors (M) | | | |
| To end users (N) | | | |

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "O"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| M + N - D - F - H = zero ("0"), if not | | | |
| revise. | 0 | 0 | 0 |

II-6c. <u>U.S. shipments by type: Japan</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of methionine imported from Japan by product type during the specified period.

Japan

| Quantity (in short tons) and value (in \$1,000) | | | |
|--|---------------|------|------|
| ltem | Calendar year | | |
| | 2018 | 2019 | 2020 |
| U.S. shipments: DL-methionine, solid-form 99 activity level: Quantity (O) | | | |
| Value (P) DL-hydroxy analogues, solid-form 84 activity level: Quantity (Q) | | | |
| Value (R) DL-hydroxy analogues, liquid- form 88 activity level: Quantity (S) | | | |
| Value (T) All other products¹: Quantity (U) | | | |
| Value (V) 1 Please specify these products: | | | |

<u>RECONCILIATION OF U.S. SHIPMENTS BY TYPE</u>.--Please ensure that the quantities and value reported for US shipments by type (i.e., lines O through V) summed across both columns equal the quantities and values reported for U.S. shipments (i.e., lines D through I) in part "a" of this question for each calendar year. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| Quantity: $O + Q + S + U - D - F - H =$ zero ("0"), if not revise. | 0 | 0 | 0 |
| Value: $P + R + T + V - E - G - I = zero$ ("0"), if not revise. | 0 | 0 | 0 |

- II-6d. Monthly U.S. imports: Japan.—Report your firm's monthly U.S. imports of methionine from Japan by supplier during the specified period.
 - Sumitomo Chemical
 - All other suppliers in Japan (Others)

| Quantity (in short tons) | | | | |
|--------------------------|-------------------|--------|--|--|
| | Supplier in Japan | | | |
| Month | Sumitomo Chemical | Others | | |
| 2020 | | | | |
| January | | | | |
| February | | | | |
| March | | | | |
| April | | | | |
| May | | | | |
| June | | | | |
| July | | | | |
| August | | | | |
| September | | | | |
| October | | | | |
| November | | | | |
| December | | | | |
| 2021 | | | | |
| January | | | | |
| February | | | | |

| RECONCILIATION OF MONTHLY IMPORTS Please ensure that the total imports reported for full year |
|--|
| 2020 reported in part "a" of this question matches the monthly data reported here. If the calculated |
| fields below return values other than zero (i.e., "0"), the data reported must be revised prior to |
| submission. |

| | Interact with check box to update the calculations presented here. |
|--|--|
| | |
| | |
| | |
| | |

| Reconciliation for | Calendar year 2020 |
|---|--------------------|
| U.S. imports from Japan (line B), revise if not | |
| returning zero ("0") | 0 |

II-6e. <u>End-of-period inventories: Japan</u>.--Report your firm's end-of-period inventories of methionine in the United States of imports from Japan at the end of the specified month by supplier.

Japan

| Quantity (in short tons) | | | | |
|--|-------------------|--------|--|--|
| | Supplier in Japan | | | |
| Date | Sumitomo Chemical | Others | | |
| Ending inventory balance on or around July 31, 2020 | | | | |
| August 31, 2020 | | | | |
| September 30, 2020 | | | | |
| October 31, 2020 | | | | |
| November 30. 2020 | | | | |
| December 31, 2020 | | | | |
| January 31, 2021 | | | | |
| February 28, 2021 | | | | |

<u>RECONCILIATION OF END-OF-PERIOD INVENTORIES</u>.-- Please ensure that the end-of-period inventories reported for December 31, 2020 in this table across all suppliers match the aggregated data reported for end-of-period inventories in part "a" of this question for calendar year 2020. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission.

| Reconciliation for | Calendar year 2020 |
|---|--------------------|
| End-of-period inventories from Japan (line L), revise | |
| if not returning zero ("0") | 0 |

II-7a. <u>U.S. imports from Spain</u>.—Report your firm's imports and your firm's shipments and inventories of methionine imported from Spain by your firm during the specified period.

Spain

| | Quantity (in short tons) | , value (<i>in \$1,000</i>) | | |
|--|---|-----------------------------------|------|--|
| | | Calendar year | | |
| Item | 2018 | 2019 | 2020 | |
| Beginning-of-period inventories (quantity) (A) | | | | |
| Imports: ¹ Quantity (B) | | | | |
| Value (C) | | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | | |
| Value (E) | | | | |
| Internal consumption: ² Quantity (F) | | | | |
| Value² (G) | | | | |
| Transfers to related firms: ² Quantity (H) | | | | |
| Value² (I) | | | | |
| Export shipments: ³ Quantity (J) | | | | |
| Value (K) | | | | |
| End-of-period inventories (quantity) (L) | | | | |
| ¹ Please identify the foreign produce ² Internal consumption and transfers basis for valuing these transactions in y the data provided above in this table sh ³ Identify your firm's principal export | to related firms must be vour records, please specify nould be based on fair marl | that basis (e.g., cost, cost plus | | |

II-7a. U.S. imports from Spain.—Continued

accurate:

<u>RECONCILIATION OF SHIPMENTS, IMPORTS, AND INVENTORIES.</u>—Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line A), plus imports (i.e., line B), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| | Calendar year | | |
|--|----------------|--|--|
| Reconciliation | 2018 2019 2020 | | |
| A + B - D - F - H - J - L = should equal | | | |
| zero ("0") or provide an explanation. ¹ 0 | | | |
| ¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless | | | |

II-7b. Channels of distribution: Spain. --Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of imports from Spain by channel of distribution during the specified period.

Spain

| | Calendar year | | |
|---|--------------------------|------|------|
| Item | 2018 | 2019 | 2020 |
| | Quantity (in short tons) | | |
| Channels of distribution: U.S. shipments: To distributors (M) | | | |
| To end users (N) | | | |

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|----------------|---|---|
| Reconciliation item | 2018 2019 2020 | | |
| M + N - D - F - H = zero ("0"), if not | | | |
| revise. | 0 | 0 | 0 |

II-7c. <u>U.S. shipments by type: Spain</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of methionine imported from Spain by product type during the specified period.

Spain

| Quantity (in short tons) and value (in \$1,000) | | | | |
|--|---------------|------|------|--|
| Item | Calendar year | | | |
| | 2018 | 2019 | 2020 | |
| U.S. shipments: DL-methionine, solid-form 99 activity level: Quantity (O) | | | | |
| Value (P) DL-hydroxy analogues, solid-form 84 activity level: Quantity (Q) | | | | |
| Value (R) | | | | |
| DL-hydroxy analogues, liquid- form 88 activity level: Quantity (S) | | | | |
| Value (T) | | | | |
| All other products¹: Quantity (U) | | | | |
| Value (V) | | | | |
| ¹ Please specify these products: | | | | |

<u>RECONCILIATION OF U.S. SHIPMENTS BY TYPE</u>.--Please ensure that the quantities and value reported for US shipments by type (i.e., lines O through V) summed across both columns equal the quantities and values reported for U.S. shipments (i.e., lines D through I) in part "a" of this question for calendar year. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| Quantity: $O + Q + S + U - D - F - H =$ zero ("0"), if not revise. | 0 | 0 | 0 |
| Value: $P + R + T + V - E - G - I = zero$ ("0"), if not revise. | 0 | 0 | 0 |

| U.S. Importers' Questionnaire - M | ethionine (Final) |
|-----------------------------------|-------------------|
|-----------------------------------|-------------------|

- II-7d. Monthly U.S. imports: Spain.—Report your firm's monthly U.S. imports of methionine from Spain by supplier during the specified period.
 - Adisseo España
 - All other suppliers in Spain (Others)

| Quantity (in short tons) | | | | |
|--------------------------|-------------------|--------|--|--|
| | Supplier in Spain | | | |
| Month | Adisseo España | Others | | |
| 2020 | | | | |
| January | | | | |
| February | | | | |
| March | | | | |
| April | | | | |
| May | | | | |
| June | | | | |
| July | | | | |
| August | | | | |
| September | | | | |
| October | | | | |
| November | | | | |
| December | | | | |
| 2021 | | | | |
| January | | | | |
| February | | | | |

<u>RECONCILIATION OF MONTHLY IMPORTS</u>.-- Please ensure that the total imports reported for full year 2020 reported in part "a" of this question matches the monthly data reported here. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission.

| | Interact with check | chox to undate th | ne calculations | presented here. |
|--|-----------------------|--------------------|-----------------|-----------------|
| | IIILEI act With Check | t box to apaate ti | ie calculations | presented nere |

| Reconciliation for | Calendar year 2020 |
|---|--------------------|
| U.S. imports from Spain (line B), revise if not | |
| returning zero ("0") | 0 |

II-7e. <u>End-of-period inventories: Spain</u>.--Report your firm's end-of-period inventories of methionine in the United States of imports from Spain at the end of the specified month by supplier.

Spain

| Quantity (in short tons) | | | |
|---|-------------------|--------|--|
| | Supplier in Spain | | |
| Date | Adisseo España | Others | |
| Ending inventory balance on or around July 31, 2020 | | | |
| August 31, 2020 | | | |
| September 30, 2020 | | | |
| October 31, 2020 | | | |
| November 30. 2020 | | | |
| December 31, 2020 | | | |
| January 31, 2021 | | | |
| February 28, 2021 | | | |

| <u>RECONCILIATION OF END-OF-PERIOD INVENTORIES</u> Please ensure that the end-of-period inventories |
|--|
| reported for December 31, 2020 in this table across all suppliers match the aggregated data reported for |
| end-of-period inventories in part "a" of this question for calendar year 2020. If the calculated fields |
| below return values other than zero (i.e., "0"), the data reported must be revised prior to submission. |

| Interact with check box to u | pdate the calculations | presented here. |
|----------------------------------|-------------------------|---------------------|
| micerace with check box to a | paate tire carearations | or cocritica rici c |

| Reconciliation for | Calendar year 2020 |
|--|--------------------|
| End of period inventories from Spain (line L), revise if | |
| not returning zero ("0") | 0 |

Imports from all other sources.—Report your firm's imports and your firm's shipments and inventories of methionine imported from all other sources by your firm during the specified period.

All other sources

| | antity (in short tons), v | aiue (<i>m \$1,000</i>) | |
|---|---------------------------|---------------------------|------|
| | Calendar year | | |
| Item | 2018 | 2019 | 2020 |
| Beginning-of-period inventories (quantity) (A) | | | |
| mports: ¹ Quantity (B) | | | |
| Value (C) | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | |
| Value (E) | | | |
| Internal consumption: ² Quantity (F) | | | |
| Value² (G) | | | |
| Transfers to related firms: ² Quantity (H) | | | |
| Value² (I) | | | |
| Export shipments: ³ Quantity (J) | | | |
| Value (K) | | | |
| End-of-period inventories | | | |

³ Identify your firm's principal export markets: _

II-8a. Imports from all other sources.—Continued

accurate:

<u>RECONCILIATION OF SHIPMENTS, IMPORTS, AND INVENTORIES.</u>--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line A), plus imports (i.e., line B), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation | 2018 | 2019 | 2020 |
| A + B - D - F - H - J - L = should equal | | | |
| zero ("0") or provide an explanation. ¹ | 0 | 0 | 0 |
| ¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless | | | |

II-8b. Channels of distribution: All other sources.-- Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of imports

from all other sources by channel of distribution during the specified period.

All other sources

| | Calendar year | | |
|---|---------------|--------------------------|------|
| Item | 2018 | 2019 | 2020 |
| | | Quantity (in short tons) | |
| Channels of distribution: U.S. shipments: To distributors (M) | | | |
| To end users (N) | | | |

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|---------------------------------------|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| M + N - D - F - H= zero ("0"), if not | | | |
| revise. | 0 | 0 | 0 |

II-8c. <u>U.S. shipments by type: All other sources</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of methionine imported from all other sources by product type during the specified period.

All other sources

| Quantity (in short tons) and value (in \$1,000) | | | | | | |
|--|---------------|------|------|---------------|--|--|
| Item | Calendar year | | | Calendar year | | |
| | 2018 | 2019 | 2020 | | | |
| U.S. shipments: DL-methionine, solid-form 99 activity level: Quantity (0) | | | | | | |
| Value (P) DL-hydroxy analogues, solid-form 84 activity level: Quantity (Q) | | | | | | |
| Value (R) DL-hydroxy analogues, liquid- form 88 activity level: Quantity (S) | | | | | | |
| Value (T) | | | | | | |
| All other products ¹ : <i>Quantity</i> (U) | | | | | | |
| Value (V) | | | | | | |
| ¹ Please specify these products: | | | | | | |

<u>RECONCILIATION OF U.S. SHIPMENTS BY TYPE</u>.--Please ensure that the quantities and value reported for US shipments by type (i.e., lines O through V) summed across both columns equal the quantities and values reported for U.S. shipments (i.e., lines D through I) in part "a" of this question for each calendar year. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | |
|--|---------------|------|------|
| Reconciliation item | 2018 | 2019 | 2020 |
| Quantity: $O + Q + S + U - D - F - H =$ zero ("0"), if not revise. | 0 | 0 | 0 |
| Value: $P + R + T + V - E - G - I = zero$ ("0"), if not revise. | 0 | 0 | 0 |

| II-9. | <u>Transfers to related firms.</u> If your firm reported transfers to related firms in any of the data tables in part II, please identify the firm(s) and indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary) and whether the transfers were priced at market value or by a non-market formula. | | | | | | | |
|-------|--|--|--|--|--|--|--|--|
| I-10. | Other explanationsIf your firm would like to further explain a response to a question in Part II for which a narrative response box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire. | | | | | | | |
| | | | | | | | | |

PART III.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Pamela Davis (202-205-2218, Pamela.Davis@usitc.gov).

III-1. <u>Contact information.</u>--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part III.

| Name | |
|-----------|--|
| Title | |
| Email | |
| Telephone | |

PRICE DATA

- III-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers since January 1, 2018 of the following products your firm imported from France, Japan, and Spain:
 - **Product 1.--** Methionine, whether DL-methionine or its hydroxy analog, 84% activity level, in dry form.
 - **Product 2.--** Methionine, whether DL-methionine or its hydroxy analog, 88% activity level, in liquid form.
 - **Product 3.--** Methionine, whether DL-methionine or its hydroxy analog, 99% activity level, in dry form.

Please note that values should be <u>f.o.b.</u>, <u>U.S. point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates). Quantities should be in short tons, 100% equivalent activity level.

III-2a. During January 2018 - December 2020, did your firm import from France, Japan, and/or Spain and sell to unrelated U.S. customers any of the above listed products (or any products that were competitive with these products)?

| YesPlease complete the following pricing data tables as appropriate. |
|--|
| NoSkip to question III-3. |

REPORT QUANTITIES ON A 100% EQUIVALENT ACTIVITY LEVEL BASIS. TO DO THIS, CONVERT YOUR ACTUAL SHORT TONS BY MULTIPLYING BY THE FOLLOWING CONVERSION FACTORS:

PRODUCT 1: SHORT TONS x 0.84
PRODUCT 2: SHORT TONS x 0.88
PRODUCT 3: SHORT TONS x 0.99

III-2b. **Price data**.--Report below the quarterly price data¹ for pricing products² imported from France and sold by your firm.

France

Report data in short tons, 100% equivalent activity level basis and actual dollars (not 1,000s).

| | Produ | ıct 1 | Produ | ıct 2 | Product 3 | | |
|---|-------------------|----------------|----------------------|-------|-----------|-------|--|
| Period of shipment | Quantity | Value | Quantity | Value | Quantity | Value | |
| 2018: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2019: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2020: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| ¹ Net values (i.e., gross sale goods), f.o.b. your firm's U.S. po the sale occurred. ² Pricing product definition | oint of shipment. | Please subtrac | ct any discounts, re | | | | |

| Note -If your firm's product does not exactly | meet the product specifications but is competitive with the specified product, |
|--|--|
| provide a description of your firm's product. | Also, please explain any anomalies in your firm's reported pricing data. |

| Product 1: | |
|------------|--|
| Product 2: | |
| Product 3: | |

III-2c. <u>Price data</u>.--Report below the quarterly price data¹ for pricing products² imported from Japan and sold by your firm.

Japan

Report data in short tons, 100% equivalent activity level basis and actual dollars (not 1,000s).

| (Quantity | in short tons | , 100% equiv | valent activity | <i>level<u>:</u></i> value | in dollars) | | |
|---|-------------------|----------------|---------------------|----------------------------|-------------|-------|--|
| | Produ | ıct 1 | Produ | ıct 2 | Product 3 | | |
| Period of shipment | Quantity | Value | Quantity | Value | Quantity | Value | |
| 2018: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2019: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2020: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| ¹ Net values (i.e., gross sale goods), f.o.b. your firm's U.S. p the sale occurred. ² Pricing product definition | oint of shipment. | Please subtrac | t any discounts, re | | | | |

| NoteIf your firm's product does not exactly | meet the product specifications but i | is competitive with the specified product, |
|---|---------------------------------------|--|
| provide a description of your firm's product. | Also, please explain any anomalies in | your firm's reported pricing data. |

| Product 1: | | | | | |
|------------|--|--|--|--|--|
| Product 2: | | | | | |
| Product 3: | | | | | |

III-2d. Price data.--Report below the quarterly price data¹ for pricing products² imported from Spain and sold by your firm.

Spain

Report data in short tons, 100% equivalent activity level basis and actual dollars (not 1,000s).

| (Quantity | in short tons, | . 100% equi | valent activity | <i>level<u>;</u></i> value | in dollars) | | |
|---|-------------------|----------------|----------------------|----------------------------|-------------|-------|--|
| | Produ | ıct 1 | Produ | ıct 2 | Product 3 | | |
| Period of shipment | Quantity | Value | Quantity | Value | Quantity | Value | |
| 2018: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2019: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| 2020: | | | | | | | |
| January-March | | | | | | | |
| April-June | | | | | | | |
| July-September | | | | | | | |
| October-December | | | | | | | |
| ¹ Net values (i.e., gross sale goods), f.o.b. your firm's U.S. pe the sale occurred. ² Pricing product definition | oint of shipment. | Please subtrac | ct any discounts, re | | | | |

| NoteIf y | our firm': | s product | does not | exactly | meet th | e product | specifica | tions but | is compe | titive with | i the spe | cified _l | produ | ct, |
|-----------|-------------|------------|-----------|---------|-----------|-----------|------------|------------|-------------|-------------|-----------|---------------------|-------|-----|
| provide a | description | on of your | firm's pr | oduct. | Also, ple | ase expla | in any and | omalies ir | n your firr | m's report | ed pricin | g data | | |

| Product 1: | |
|------------|--|
| Product 2: | |
| Product 3: | |

III-2e. <u>Price data checklist.</u>--Please check that the pricing data in question III-2(b)-III-2(d) has been correctly reported.

| | Are the price data reported above: | √ if Yes |
|---------|--|-------------|
| | In actual dollars (not \$1,000)? | |
| | In short tons, 100% equivalent activity level? | |
| | F.o.b. U.S. point of shipment (i.e., does not include U.S. transport costs)? | |
| | Net of all discounts and rebates? | |
| | Have discounts, rebates, and returns been credited to the quarter in which the sale occurred? | |
| | Quantities do not exceed commercial shipments in questions II-5 to II-7 in each year? | |
| | Explanation(s) for any boxes not checked: | |
| III-2f. | Pricing data methodologyPlease describe the method and the kinds of documer that were used to compile your price data. | nts/records |

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the price data, as Commission staff may contact your firm regarding questions on the price data. The Commission may also request that your company submit copies of the supporting documents/records (such as sales journal, invoices, etc.) used to compile these data.

| 115 | Importers' | Question | naire . | - Methionine | (Final) |
|------|-------------|----------|---------|-------------------|---------|
| U.S. | illiporters | Question | ınane : | - ivietillollille | Trillai |

| III-3. | <u>Price setting.</u> How does your firm determine the prices that it charges for sales of methionine |
|--------|---|
| | (check all that apply)? If your firm issues price lists, please submit sample pages of a recent list. |

| Transaction by transaction | Contracts | Set price lists | Other | If other, describe |
|----------------------------------|-----------|-----------------------|-------|--------------------|
| | | | | |

III-4. <u>Bundling.--</u> Do you sell methionine as a part of multiple products related to agricultural feed?

| No | Yes | If yes, are they sold on the same invoice? Please explain what other products or prices your firm sells in the same order, if it affects the prices of methionine, and if this forms part of a global, multiproduct strategy. | | | | |
|----|-----|---|-----|--|--|--|
| | | No | Yes | | | |
| | | | | | | |

III-5. <u>Discount policy</u>.--Please indicate and describe your firm's discount policies (*check all that apply*).

| Quantity discounts | Annual total volume discounts | No discount policy | Other | Describe |
|-----------------------|--|--------------------------|-------|----------|
| | | | | |

III-6. **Pricing terms.**--On what basis are your firm's prices of imported methionine from France, Japan, and Spain usually quoted *(check one)*?

| Delivered | | F.o.b. | If f.o.b., specify point |
|-----------|--|--------|--------------------------|
| | | | |

III-7. <u>Contract versus spot.</u>--Approximately what share of your firm's sales of methionine imported from France, Japan, and Spain in 2020 was on a (1) short-term contract basis, (2) annual contract basis, (3) long-term contract basis, and (4) spot sales basis?

| | Type of sale | | | | | |
|---------------------|--|--|---|---|---------------------------------------|---|
| ltem | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) | Spot sales (for a single delivery) | Total (should sum to 100.0%) | |
| Share of 2020 sales | % | % | % | % | 0.0 | % |

III-8. <u>Contract provisions.</u>--Please fill out the table regarding your firm's typical sales contracts for methionine imported from France, Japan, and Spain (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

| Typical sales contract provisions | ltem | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) |
|-------------------------------------|----------------|--|---|--|
| Average contract duration | No. of days | | 365 | |
| Price renegotiation | Yes | | | |
| (during contract period) | No | | | |
| | Quantity | | | |
| Fixed quantity and/or price | Price | | | |
| aa, a. pa | Both | | | |
| Indexed to raw | Yes | | | |
| material costs ¹ | No | | | |
| Not applicable | | | | |
| ¹ Please identify the in | dexes used: | · | | |

III-9. <u>Lead times.</u>--What is your firm's share of sales of methionine imported from France, Japan, and Spain from inventory and produced to order and what is the typical lead time between a customer's order and the date of delivery for your firm's sales of methionine?

| Source | Share of 2019 sales | Lead time (Average number of days) |
|---------------------------------------|---------------------|--|
| From your firm's U.S. inventory | % | |
| From foreign manufacturers' inventory | % | |
| Produced to order | % | |
| Total (should sum to 100.0%) | 0.0 % | |

| | • | | | |
|---------|----------------|---|-------------------|--------------------|
| III-10. | <u>Shippir</u> | ng information.— | | |
| | (a) | Who generally arranges the transportation to your fir Your firm Purchaser (check one) | m's customers' lo | ocations? |
| | (b) | When your firm sells methionine imported from Francit shipped? Point of importation Storage facility (check on | | ain, from where is |
| | (c) | Indicate the approximate percentage of your firm's saffrance, Japan, and Spain that are delivered the follow point of shipment. | | • |
| | | Distance from your firm's U.S. point of shipment | Share | |
| | | Within 100 miles | % | |

| Distance from your firm's U.S. point of shipment | Share |
|--|-------|
| Within 100 miles | % |
| 101 to 1,000 miles | % |
| Over 1,000 miles | % |
| Total (should sum to 100.0%) | 0.0 % |

III-11. <u>Geographical shipments.</u>—In which U.S. geographic market area(s) has your firm sold methionine imported from subject countries since January 1, 2018 (check all that apply)?

| Geographic area | France | Japan | Spain |
|--|--------|-------|-------|
| Northeast.–CT, ME, MA, NH, NJ, NY, PA, RI, and VT. | | | |
| Midwest.—IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI. | | | |
| Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV. | | | |
| Central Southwest.—AR, LA, OK, and TX. | | | |
| Mountains.—AZ, CO, ID, MT, NV, NM, UT, and WY. | | | |
| Pacific Coast.—CA, OR, and WA. | | | |
| Other.—All other markets in the United States not previously listed, including AK, HI, PR, and VI. | | | |

| III-12. | Inland transp | <u>ortation costs.</u> —What is the approximate percentage of the cost of methionine |
|---------|---------------|--|
| | imported fro | m France, Japan, and Spain that is accounted for by U.S. inland transportation |
| | costs? | percent. |

III-13. <u>End uses.--</u>List the end uses of the methionine that your firm imports. For each end-use product, what percentage of the <u>total cost</u> is accounted for by methionine and other inputs?

| | Share of total cost of end-use product accounted for by | | Total |
|-----------------|---|--------------|----------------|
| | | | (should sum to |
| End-use product | Methionine | Other inputs | 100.0% across) |
| | % | % | 0.0 % |
| | % | % | 0.0 % |
| | % | % | 0.0 % |

| | | | | 70 | | | 70 | 0.0 % |
|------|---------------------------|------------|--------------------------|-------------------------------|----------------------|-----------------|--|------------------|
| | | | | % | | | % | 0.0 % |
| I-: | 14. Substitutes. - | -Can other | | oe substitut lease fill ou | | | nine? | |
| | | F | nd use in v | which this | На | | anges in the price | |
| | Substitute | - | substitute | | No | Yes | Expl | anation |
| 1. | | | | | | | | |
| 2. | | | | | | | | |
| 3. | | | | | | | | |
| 11-: | States (if kno | wn) for me | thionine h ctors that | as changed have affect | since Ja ed these | nuary e chan | states and outside 1, 2018. Explain ges in demand. | |
| | Market | increase | No change | Overall decrease | Fluctua no clea | | | tion and factors |
| W | ithin the United | | | | | | | |
| Sta | | ì | | İ | | | | |

| III-16. | | | | eve there been any significant changes in the product range, product mix or nine since January 1, 2018? | | | |
|---------|--|-------------------------|--|--|--|--|--|
| | No | Yes | If yes, please des | cribe. | | | |
| | | | | | | | |
| III-17. | Conditions | s of comp | etition.— | | | | |
| | (a) Is the methionine market subject to business cycles (other than general economy-wide conditions) and/or other conditions of competition distinctive to methionine? | | | | | | |
| | Check all | that apply | / . | Please describe. | | | |
| | | No | | Skip to question III-18. | | | |
| | | Yes-Busin seasonal | iess cycles (e.g. business) | | | | |
| | Yes-Other distinctive conditions of competition | | | | | | |
| | | | e been any change e January 1, 2018? | es in the business cycles or conditions of competition for | | | |
| | No | Yes | If yes, describe | e. | | | |
| | | | | | | | |
| III-18. | January 1, declining t | 2018 (exa o accept r | imples include place new customers or | used, declined, or been unable to supply methionine since cing customers on allocation or "controlled order entry," renew existing customers, delivering less than the eet timely shipment commitments, etc.)? | | | |
| | No | Yes | If yes, please des | cribe. | | | |
| | | | | | | | |
| | | | | | | | |

| U.S. Importers' Questionnaire - Methionine (Final | U.S. Ir | mporters' | Questionnaire | - Methionine | (Final |
|---|---------|-----------|---------------|--------------|--------|
|---|---------|-----------|---------------|--------------|--------|

| III-19. | Impact of section 301 tariffs Did the imposition of tariffs on Chinese-origin products under |
|---------|--|
| | Section 301 have an impact on the methionine market in the United States? |

| Yes — Please indicate the impact in the table below. | No | Don't know |
|---|----|------------|
| | | |

| Factor | Overall increase | No change | Overall decrease | Fluctuate with no clear trend | Explain, noting how the imposition of tariffs under section 301 affected each factor of the methionine market in the United States. |
|---|------------------|--------------|------------------|--|---|
| Supply of U.S produced methionine | | | | | |
| Supply of methionine imported from China | | | | | |
| Supply of methionine imported from France | | | | | |
| Supply of methionine imported from Japan | | | | | |
| Supply of methionine imported from Spain | | | | | |
| Prices for methionine | | | | | |
| Overall U.S. demand for methionine | | | | | |
| Raw material costs for methionine | | | | | |

III-20. Raw materials.--How have methionine raw material prices changed since January 1, 2018?

| Overall increase | No change | Overall decrease | Fluctuate with no clear trend | Explain, noting how raw material price changes have affected your firm's selling prices for methionine. |
|------------------|--------------|------------------|-------------------------------------|---|
| | | | | |

| us i | mnorters' | Questionnaire - | Methionine (| (Final) |
|---------|------------|-----------------|-------------------|-------------------|
| U.J. II | ilipolicis | Questionnane | IVIC CITIOTITIC (| (1 111a1 <i>)</i> |

| III-21. | Price indices. — Does your firm refer to or otherwise rely on any domestic or global published |
|---------|--|
| | price information when negotiating spot or contract prices with your methionine suppliers? |
| | (Respond yes to all types of purchases in which you use published pricing information). |

| No | Yes for spot prices | Yes for contract | If "Yes," identify the source(s) on which you rely for this methionine pricing, the specific pricing data set(s) you use from these sources, and how that information is used in your firm's pricing decisions. Submit these data as an attachment to the questionnaire. |
|----|------------------------------|------------------|--|
| | | | |

| III-22 | Non-U.S. | nrices — |
|---------|------------|----------|
| 111-22. | 14011-0.3. | prices.— |

| (a | a) | Is١ | our firm | familiar wit | h non-U.S. | prices o | of methionine? |
|----|----|-----|----------|--------------|------------|----------|----------------|
|----|----|-----|----------|--------------|------------|----------|----------------|

| No | Yes – please answer (b) |
|----|-------------------------|
| | |

(b) Are non-U.S. prices referenced in negotiations with your methionine purchasers?

| No | Yes | Explain, noting what price(s) your firm referenced |
|----|-----|--|
| | | |

(c) Are U.S. prices generally higher than, about the same as, or lower than non-U.S. methionine prices?

| Higher | About the same | Lower |
|--------|----------------|-------|
| | | |

(d) Do U.S. price changes lead, trail, or move simultaneously with non-U.S. prices?

| Lead | Move simultaneously | Follow | If your answer would differ among countries of comparison, please list those countries and the difference(s). |
|------|---------------------|--------|---|
| | | | |

(e) Since January 1, 2018, what are the major factors that have influenced non-U.S. prices?

| No | Yes | Explain, noting what price(s) your firm referenced |
|----|-----|--|
| | | |

| III-23. | Activity | level. |
|---------|----------|--------|
|---------|----------|--------|

| (| (a) | ls activity | / level | considered | in pr | ice det | erminati | ons for | methi | onine? |
|---|-----|---------------|-----------|------------|--------|---------|-------------|----------|---------|--------|
| ١ | (u | , is activity | , 10 0 01 | CONSIDERCA | III PI | ice act | CITITITIALI | 0113 101 | HICKIII | |

| No | Yes | If yes, please explain. |
|----|-----|-------------------------|
| | | |

(b) After controlling for activity levels, are methionine products of different activity levels comparable?

| Fully Mostly | | Somewhat | Not at all | |
|--------------|--|----------|------------|--|
| | | | | |

| (C) | if your answer | airrers than | Tully | or | mostly | , piease ex | piain. | |
|-----|----------------|--------------|-------|----|--------|-------------|--------|--|
| | | | | | | | | |
| | | | | | | | | |

III-24. <u>Interchangeability.--</u>Is methionine produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = *no familiarity* with products from a specified country-pair

| Country-pair | France | Japan | Spain | Other countries |
|---------------|--------|-------|-------|-----------------|
| United States | | | | |
| France | | | | |
| Japan | | | | |
| Spain | | | | |

For any country-pair producing methionine that is *sometimes* or *never* interchangeable, identify the country-pair and explain the factors that limit or preclude interchangeable use:

III-25. **Factors other than price.**--Are differences other than price (e.g., quality, availability, transportation network, product range, technical support, *etc.*) between methionine produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = *no familiarity* with products from a specified country-pair

| Country-pair | France | Japan | Spain | Other countries |
|---------------|--------|-------|-------|-----------------|
| United States | | | | |
| France | | | | |
| Japan | | | | |
| Spain | | | | |

For any country-pair for which factors other than price *always* or *frequently* are a significant factor in your firm's sales of methionine, identify the country-pair and report the advantages or disadvantages imparted by such factors:

III-26. <u>Customer identification</u>.--List the names and contact information for your firm's 10 largest U.S. customers for methionine since January 1, 2018. Indicate the share of the quantity of your firm's total shipments of methionine that each of these customers accounted for in 2020.

| Customer's name | | Contact person | Email | Telephone | City | State | Share of 2020 sales (%) |
|-----------------|--|----------------|-------|-----------|------|-------|-------------------------------------|
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| 6 | | | | | | | |
| 7 | | | | | | | |
| 8 | | | | | | | |
| 9 | | | | | | | |
| 10 | | | | | | | |

| III-2 | for which a na explanation ir firm had in pr | Other explanationsIf your firm would like to further explain a response to a question in Part III for which a narrative response box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire. | | | | | | | | | |
|-------|--|---|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | |


Correcting valid number error messages.--If you are completing a Commission questionnaire in a country that uses periods (".") to delineate multiples of 1000 (e.g., one million would appear as \$1.000.000 instead of as \$1,000,000), you may be unable to enter in numbers greater than 999 in numeric form fields. This issues stem from your computer number formatting setting (e.g., not the MS Word document itself, but the computer from which you are opening up the document). In the United States commas (,) delineate multiples of 1000 and periods (.) delineate fractions less than one. Many EU countries use the reverse where multiples of 1000 are delineated with periods (.) and fractions less than one are delineated with commas (,). The U.S. International Trade Commission's questionnaires are setup in the United States with the U.S. number formatting. When this formatting interacts with a computer set to EU number formatting, we believe this may cause this issue.


The solution to this data entry issue is to temporarily change your operating system's number formatting to be consistent with the U.S. number formatting system while you complete the questionnaire.

To temporarily change your computer's number settings to U.S. settings, please do the following (for Microsoft Windows Operating system):

- START
- Control Panel
- Region and Language (under Clock, Language, and Region category)
- Format tab
- Change the Format from your existing one (e.g. "Italian (Italy)") to "English (United States)" (see screen shots below)

When you do this the number "twelve million dollars and thirty five cents" would change from \$12.000.000,35 (Italy format) to \$12,000,000.35 (U.S. format), and then there will be no conflict with the questionnaire. When you finish reporting the data then you can close the questionnaire and switch back to Italy settings.





HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://www.usitc.gov/investigations/701731/2020/methionine france japan and spa in/final.htm

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Secure Drop Box</u>.—Upload the MS Word questionnaire along with a scanned copy of the signed certification page (page 1) through the Commission's secure upload facility:

Web address: https://dropbox.usitc.gov/oinv/ PIN: MET

• E-mail.—E-mail the MS Word questionnaire to calvin.chang@usitc.gov; include a scanned copy of the signed certification page (page 1). Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure drop-box system and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm did not import this product, please fill out page 1, print, sign, and submit a scanned copy to the Commission.

<u>Parties to this proceeding</u>.—If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1803). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.